On June 22^th, an article A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 ¹ was published on Science. Researchers pointed out the NTD as a promising target for therapeutic mAbs against COVID-19.

Figure.1 Immobilized SARS-CoV-2 S1 protein NTD, His Tag (Cat. No. S1D-C52H6) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike NTD Antibody, Chimeric mAb (Cat. No. SPD-M121) with a linear range of 0.1-3 ng/mL.

Figure. 2 Loaded Anti-SARS-CoV-2 Spike NTD Antibody, Chimeric mAb (Cat. No. SPD-M121) on AHC Biosensor, can bind SARS-CoV-2 S1 protein NTD, His Tag (Cat. No. S1D-C52H6) with an affinity constant of 39.8 nM as determined in BLI assay (ForteBio Octet Red96e)

Figure. 3 Anti-SARS-CoV-2 Spike NTD Antibody, Chimeric mAb (Cat. No. SPD-M121) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S1 protein NTD, His Tag (Cat. No. S1D-C52H6) with an affinity constant of 74.6 nM as determined in a SPR assay (Biacore T200)

All Spike Protein List

>>> Click to check more SARS-CoV-2 related products

>>> Click to check more antigens & antibodies for diagnostic kit development

Reference

1.    Chi X. et al., A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020, DOI: 10.1126/science.abc6952